11 new pieces of shared-use equipment and an additional offer in cellular biology
Genopole earmarked €1.6 million in 2022 to ensure that its current equipment was maintained to the highest standards and to acquire novel equipment responding to the new needs of its actors or to the evolution of techniques. Particularly, a high-resolution mass spectrometer, a digital PCR system, a multimode microplate reader, a pipetting robot, a device for in-gel protein quantification and study and an integrated system of 48 microfermentors were brought in to strengthen the offer. France has only three structures currently equipped with the microfermentor system, which, at Genopole, will be managed by the start-up Nutropy and mutualized to accelerate the development of bioprocesses for the production of compound of interest in food, therapeutics, industry and more.
The cellular biology platform at I-Stem has also joined the Genopole shared-use offer. Able to perform all steps in cell-line creation, genomic control and master cell banking, this platform will provide biocluster actors with a new service in tailored cell production, potentially useful in, for example, research on biological or pathological mechanisms, or in therapeutic compound screening.
The DNA & Cells Bank, a key contributor to the innovative therapies sector at Genopole, was equipped with two additional nitrogen tanks. As Europe's leading bank for rare genetic diseases, it conserves more than 430,000 samples and processes 3,000 new samples of patient and patient-family blood or DNA yearly.
Also contributing to the growth of biotherapies is the laboratory Cithera, a center for cellular bioengineering innovation, which is currently establishing a national, clinical-grade iPS cell bank at Genopole. In 2022, Cithera benefited from 26 dedicated scientific instruments: epifluorescent video microscopes, CO2 incubators, vacuum systems, etc.